Research Progress in Population Pharmacokinetics of Multiple Target Tyrosine Kinase Inhibitors in the Treatment of Malignant Tumors / 中国药学杂志

ABSTRACT

Multiple target tyrosine kinase inhibitors are commonly used in clinical as anti-tumor drugs, which can promote tumor cell apoptosis by inhibiting cell signal transduction, with high selectivity and few side effects. At present, it is widely used in the treatment of non-small cell lung cancer, metastatic renal cancer, thyroid cancer and hematological malignancies. However, the clinical efficacy and pharmacokinetic characteristics of these drugs are affected by many factors, and there are great individual differences. In recent years, the study of population pharmacokinetics is emerging and is widely used in the study of many drugs. In this paper, the pharmacokinetic characteristics and influencing factors of axitinib, imatinib, erlotinib and sunitinib in cancer patients and healthy people were summarized through the retrieval of relevant literature, and then the progress of pharmacokinetic research of tyrosine kinase inhibitors(TKIs) was reviewed. The pharmacokinetic characteristics in different tumor types were analyzed and the related covariates were summarized. The results showed that demographic factors, gene polymorphism, blood biochemical indexes, combined use of drugs and liver and kidney function were important factors affecting metabolism in vivo. Factors such as experimental design and model construction may be the important reasons for the differences in research results. The purpose of this study is to provide a reference for making a reasonable and safe drug therapy plan.